SCHEMBL20550778

SCHEMBL20550778

Cc1nn(-c2ccc(F)cc2Cl)c(N)c1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
MARS1 P56192 1/20 0.43
P2RX7 Q99572 6/20 0.41
SCN9A Q15858 2/20 0.41
HPGD P15428 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRE P78334 1/20 0.40
GABRA6 Q16445 1/20 0.40
GABRG1 Q8N1C3 1/20 0.40
GABRG3 Q99928 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22286202 0.87 LMNA (0.44) LMNASCN9AHPGDGABRPGABRD
SCHEMBL20552156 0.84 PDE4B (0.55) LMNASCN9AHPGDGABRPGABRD
SCHEMBL20551576 0.78 HPGD (0.56) LMNAHPGDSMN1; SMN2SRCKDR
SCHEMBL20551413 0.78 LMNA (0.43) LMNAP2RX7SCN9AHPGDALDH1A1
SCHEMBL20552352 0.77 PDE4B (0.47) LMNAP2RX7SCN9AHPGDALDH1A1
SCHEMBL20551408 0.76 HPGD (0.54) P2RX7HPGDSMN1; SMN2POLBCYP1A2
SCHEMBL13982935 0.76 SCN9A (0.56) SCN9AHPGDALDH1A1SMN1; SMN2POLB
SCHEMBL31673548 0.73 LMNA (0.59) LMNAP2RX7POLBCYP1A2CYP3A4
SCHEMBL20551308 0.72 HPGD (0.49) LMNAP2RX7SCN9AHPGDALDH1A1
SCHEMBL13982920 0.72 HPGD (0.56) LMNAHPGDALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2020-08-06 US disclosed
CN-110914263-A Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors 格兰马克药品股份有限公司 2020-03-24 CN disclosed
EP-3619209-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS Glenmark Pharmaceuticals S.A. (CH) 2020-03-11 EP disclosed
WO-2018203298-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2018-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS NOX1, CYBB, NOX4 LMNA 3874/4885MARS1 3540/4885P2RX7 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.